title: Quantification of CD34+ cells mobilized into the peripheral blood predicts the yield of the leukapheresis product and can replace progenitor assays.
abstract: We reviewed 333 concomitant blood and cytapheresis samples from 101 patients with solid malignancies of various histological cell types. All samples were analyzed for CFU-GM, BFU-E and CD34+ determination. We found a good correlation between progenitor assays CFU-GM and CD34+ determination in the blood and cytapheresis (r = 0.77, p < 0.0001 and r = 0.79, p < 0.0001 respectively). The number of CD34+ cells in the peripheral blood was predictive of the CD34+ yield in the cytapheresis (r = 0.86, p < 0.0001), and we determined that a threshold of 26 CD34+/microliter of blood was sufficient to harvest 10(6) CD34+/kg in a single apheresis. Thirty breast cancer patients received injections of peripheral blood stem cells after the same high-dose chemotherapy. For these patients, we found a significant correlation between the quantity of CD34+ cells or CFU-GM collected and both granulocyte and platelet recovery. In conclusion, there is a very good correlation between CFU-GM assays and CD34+ determination and a good correlation between circulating CD34+ cells and the yield obtained by the cytapheresis. The number of CD34+ cells collected is also significantly correlated with hematological recovery. Because CD34+ quantification is an accurate, fast and inexpensive technique, this can lead to the progressive forsaking of progenitor assays in a clinical setting.
authors.affiliation: Laboratory of Experimental Oncology and Hematology, Catholic University of Louvain, Brussels, Belgium.
authors.forename: L
authors.initials: L
authors.lastname: D'Hondt
authors.forename: M
authors.initials: M
authors.lastname: André
authors.forename: T
authors.initials: T
authors.lastname: Guillaume
authors.forename: A M
authors.initials: AM
authors.lastname: Feyens
authors.forename: Y
authors.initials: Y
authors.lastname: Humblet
authors.forename: C
authors.initials: C
authors.lastname: Doyen
authors.forename: A
authors.initials: A
authors.lastname: Bosly
authors.forename: A
authors.initials: A
authors.lastname: Dromelet
authors.forename: B
authors.initials: B
authors.lastname: Chatelain
authors.forename: M
authors.initials: M
authors.lastname: Symann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000097:blood*; D001772:Blood Cell Count; D001943:Breast Neoplasms / Q000097:blood / Q000628:therapy; D003114:Colony-Forming Units Assay; D005260:Female; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000276:immunology*; D006801:Humans; D007937:Leukapheresis; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000628:therapy; D012189:Retrospective Studies; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34